Key result
Acetylcholinesterase inhibitors may improve autonomic and cardiac function in acute myocardial infarction and heart failure, though their exact clinical role remains unclear.
Why the study?
Despite potential clinical benefits for cardiovascular disease patients, the role of acetylcholinesterase inhibitors in acute myocardial infarction and heart failure remediation remains unclear.
Do acetylcholinesterase inhibitors improve cardiac outcomes in acute myocardial infarction and heart failure?
Do acetylcholinesterase inhibitors improve cardiac outcomes in acute myocardial infarction and heart failure?
Answers are grounded in this paper and cite their sources.
Acetylcholinesterase inhibitors represent a potential therapeutic approach to moderate parasympathetic activity and improve cardiac function in acute myocardial infarction and heart failure.
Cardiovascular diseases remain a major cause of morbidity and mortality worldwide. Cardiovascular diseases such as acute myocardial infarction, ischaemia/reperfusion injury and heart failure are associated with cardiac autonomic imbalance characterized by sympathetic overactivity and parasympathetic withdrawal from the heart. Increased parasympathetic activity by electrical vagal nerve stimulation has been shown to provide beneficial effects in the case of cardiovascular diseases in both animals and patients by improving autonomic function, cardiac remodelling and mitochondrial function. However, clinical limitations for electrical vagal nerve stimulation exist because of its invasive nature, costly equipment and limited clinical validation. Therefore, novel therapeutic approaches which moderate parasympathetic activities could be beneficial for in the case of cardiovascular disease. Acetylcholinesterase inhibitors inhibit acetylcholinesterase and hence increase cholinergic transmission. Recent studies have reported that acetylcholinesterase inhibitors improve autonomic function and cardiac function in cardiovascular disease models. Despite its potential clinical benefits for cardiovascular disease patients, the role of acetylcholinesterase inhibitors in acute myocardial infarction and heart failure remediation remains unclear. This article comprehensively reviews the effects of acetylcholinesterase inhibitors on the heart in acute myocardial infarction and heart failure scenarios from in vitro and in vivo studies to clinical reports. The mechanisms involved are also discussed in this review.
No takes yet. Share an insight, caveat, or question.
Khuanjing et al. (2019) conducted a review in Acute myocardial infarction and heart failure. Acetylcholinesterase inhibitors was evaluated. Acetylcholinesterase inhibitors may improve autonomic and cardiac function in acute myocardial infarction and heart failure, though their exact clinical role remains unclear.
Synapse has enriched 10 related papers. Consider them for comparative context: